Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 17/20 | 0.69 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.56 |
| ▸ | CDK4 | P11802 | 1/20 | 0.52 |
| ▸ | CCND1 | P24385 | 1/20 | 0.52 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.52 |
| ▸ | CDK2 | P24941 | 1/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.52 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13638219 | 0.91 | BRD4 (0.68) | BRD4PKMYT1CDK4CCND1CCNE1 | |
| SCHEMBL13638218 | 0.91 | BRD4 (0.84) | BRD4 | |
| SCHEMBL265286 | 0.88 | BRD4 (0.84) | BRD4 | |
| SCHEMBL300559 | 0.82 | BRD4 (0.64) | BRD4CDK4PDGFRBPDGFRA | |
| SCHEMBL17526080 | 0.82 | BRD4 (1.00) | BRD4 | |
| SCHEMBL30306426 | 0.82 | BRD4 (1.00) | BRD4 | |
| SCHEMBL306558 | 0.81 | BRD4 (0.55) | BRD4PKMYT1PDGFRBPDGFRA | |
| SCHEMBL271227 | 0.81 | BRD4 (0.66) | BRD4CDK2PDGFRBPDGFRA | |
| SCHEMBL270973 | 0.80 | BRD4 (0.71) | BRD4 | |
| SCHEMBL265038 | 0.80 | BRD4 (1.00) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286789-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | TARGEGEN, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090275582-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | IMPACT BIOMEDICINES, INC. | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286789-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | JAK2, TYK2, LTK | BRD4 156/4885PKMYT1 1031/4885CDK4 443/4885 |
| US-20090275582-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | JAK2, TYK2, JAK3 | BRD4 142/4885PKMYT1 470/4885CDK4 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.